Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.

Journal of clinical pharmacology - 1 Jan 2003

Lee Craig R, Pieper John A, Frye Reginald F, Hinderliter Alan L, Blaisdell Joyce A, Goldstein Joyce A

Abstract excerpt

The metabolic activity of CYP2C9 in 16 subjects expressing four different genotypes (CYP2C9*1/*1, *1/*2, *1/*3, and *2/*2) was evaluated. Single oral doses of tolbutamide, flurbiprofen, and losartan were administered in a randomized, crossover design. Plasma and urine were collected over 24 hours. The urinary metabolic ratio and amount of metabolite(s) excreted were correlated with formation clearance. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Genotype

Share to Losartan

Share to Phenotype

Source

Identifiers

PMID: 12520632
DOI: 10.1177/0091270002239710

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.PMID 12520632Read ↗

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.Semantic proximity Read ↗

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.Semantic proximity Read ↗

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.Semantic proximity Read ↗

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants.Semantic proximity Read ↗

Phenotypic analysis of human CYP2C9 polymorphisms using fluorine-substituted tolbutamide.Semantic proximity Read ↗

CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.Semantic proximity Read ↗

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.Semantic proximity Read ↗

Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans.Semantic proximity Read ↗

In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.Semantic proximity Read ↗

Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.Semantic proximity Read ↗

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.